

Publikationen der MDS-Gruppe im Jahre 2010

(Stand: 20.09.2010)

1) Evaluation of the prognostic significance of eosinophilia and basophilia in a larger cohort of patients with myelodysplastic syndromes. Wimazal F, Germing U, Kundi M, Noesslinger T, Blum S, Geissler P, Baumgartner C, Pfeilstoecker M, Valent P, Sperr WR. *Cancer*. 2010 May 15; 116(10):2372-81.

2) Serum CD44 levels predict survival in patients with low-risk myelodysplastic syndromes. Loeffler-Ragg J, Germing U, Sperr WR, Herrmann H, Zwierzina H, Valent P, Ulmer H, Stauder R. *Crit Rev Oncol Hematol*. 2010 Jun 26.

3) Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group. Götze K, Platzbecker U, Giagounidis A, Haase D, Lübbert M, Aul C, Ganser A, Germing U, Hofmann WK. *Ann Hematol*. 2010 Sep; 89(9):841-50.

4) 5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis. Czibere A, Bruns I, Kröger N, Platzbecker U, Lind J, Zohren F, Fenk R, Germing U, Schröder T, Gräf T, Haas R, Kobbe G. *Bone Marrow Transplant*. 2010 May;45(5):872-6

5) Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes. Nösslinger T, Tüchler H, Germing U, Sperr WR, Krieger O, Haase D, Lübbert M, Stauder R, Giagounidis A, Valent P, Pfeilstöcker M. *Ann Oncol*. 2010 Jan;21(1):120-5.